Abstract
Lysins are direct lytic agents which act through enzymatic cell-wall-hydrolysis and represent a potential new class of antimicrobial agents in development to treat antibiotic-resistant bacterial infections. Exebacase (CF-301) is a first-in-class lysin now in clinical development for the treatment of Staphylococcus aureus (S. aureus) bacteremia and infective endocarditis (IE) when used in addition to conventional antibiotics. Exebacase and comparator antibiotics were tested by broth microdilution against a set of 535 clinical MSSA and MRSA isolates collected from 2015 to 2017 throughout the United States, Europe and South America. All S. aureus isolates were inhibited by ≤1 mg/L exebacase (MIC50/90, 0.5/1 mg/L) with a range of 0.25–1 mg/L. No difference in susceptibility was observed between the MSSA and MRSA isolates. Exebacase was uniformly and equivalently active against all recent clinical MSSA and MRSA surveillance isolates from a broad survey across 3 continents.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.